Hepatitis C virus infection in Taiwan: Past, present, and future  by Kao, Jia-Horng
Journal of the Formosan Medical Association (2016) 115, 65e66Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comPERSPECTIVESHepatitis C virus infection in Taiwan:
Past, present, and future
Jia-Horng Kao a,b,*a Department of Internal Medicine, National Taiwan University Hospital, Graduate Institute of Clinical
Medicine, Hepatitis Research Center, Taipei, Taiwan
b Department of Medical Research, National Taiwan University College of Medicine and National
Taiwan University Hospital, Taipei, TaiwanReceived 17 June 2015; accepted 23 June 2015Hepatitis C virus (HCV) infection is a global health problem,
with 170 million people chronically infected with HCV
worldwide. Chronic hepatitis C (CHC) is the leading cause of
cirrhosis, hepatic decompensation, and hepatocellular
carcinoma (HCC).1 Therefore, prevention of HCV trans-
mission and early intervention of HCV infection are urgently
needed to reduce or halt the liver-related morbidity and
mortality. The HCV viral genome was first discovered in
1989, and the complete nucleotide sequence of Taiwanese
HCV genome was subsequently determined from a patient
with post-transfusion hepatitis C in 1992.2 Currently, seven
major HCV genotypes and at least 60 subtypes have been
identified, with varied geographical distribution. Among
major genotypes, HCV genotype 1 is prevalent around the
world. In Taiwan, HCV subtypes 1b and 2a are the major
subtypes.1
The first clinical trial using combination of standard
interferon (IFN) plus ribavirin (RBV) for the treatment of
CHC was conducted in Taiwan,2 and the combination of
pegylated IFN (PEG-IFN) plus RBV therapy became the
standard of care from 2004 to 2011, with an overall sus-
tained virologic response (SVR) rate of 54e63% in western
CHC patients.1 A 48-week course of combination therapy
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viral (DAA) era. However, about 50e60% of CHC patients
still do not respond to the combination therapy. In contrast,
studies for Asian HCV genotype 1 patients showed a favor-
able treatment response to combination therapy.3 With the
introduction of early viral kinetics and response-guided
therapy, HCV genotype 1 patients who have low baseline
viral load and who achieve rapid virologic response, a
truncated duration of therapy from 48 weeks to 24 weeks
would have comparable SVR rates.1 Recent large-scale
follow-up studies indicated that CHC patients with SVR
have improved hepatic and extrahepatic outcomes,
including the reduction of HCC risk and better renal/cir-
culatory consequences.4
Many pretreatment factors, including age, sex, body
mass index, insulin resistance, hepatic steatosis/fibrosis,
ethnicity, and viral load, are associated with SVR. Among
them, single nucleotide polymorphisms near the interleukin
28B gene (rs8099917 and rs12979860) are found to be
associated with spontaneous or treatment-induced viral
clearance, and early viral kinetics to treatment in HCV
genotype 1 patients.5 In addition, microRNA-122 (miR-122)
is shown to facilitate HCV replication in vitro, and serum
miR-122 may be implicated as a biomarker for various liver
diseases. A recent study suggested that serum miR-122 may
serve as a surrogate of hepatic miR-122, and a higher pre-
treatment serum miR-122 level can help predict SVR to
combination therapy.6
Although the treatment response to PEG-IFN and RBV in
Taiwanese HCV genotype 1 patients is satisfactory, the
ineligibility and treatment-related adverse events duringAssociation. All rights reserved.
Table 1 Current interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C.
NS3/4A protease inhibitor NS5A inhibitor NS5B nucleotide analog NS5B non-nucleotide
analog
Ribavirin
Paritaprevir/ritonavir Obmitasvir Dasabuvir  Ribavirin
Asunaprevir Daclatasvir  Beclabuvir  Ribavirin
Grazoprevir Elbasvir  Ribavirin
Ledipasvir Sofosbuvir  Ribavirin
Daclatasvir Sofosbuvir  Ribavirin
Simeprevir Sofosbuvir  Ribavirin
Sofosbuvir Ribavirin
66 J.-H. Kaocombination therapy would raise safety concerns, espe-
cially in older patients and those with various comorbid-
ities.7 With the introduction of novel DAAs targeting at the
replication process of HCV, a paradigm shift of HCV treat-
ment occurs. In early 2011, the first-generation protease
inhibitors, telaprevir and boceprevir, achieved significantly
higher SVR rates in HCV genotype 1 patients when they
were used in combination with PEG-IFN and RBV. However,
the use of telaprevir and boceprevir would increase pill
burdens, and treatment-emergent adverse events. A little
later, the newer protease inhibitors, simeprevir and sofos-
buvir, showed even better SVR rates in treatment-naı¨ve and
-experienced HCV genotype 1 patients. However, the ex-
pected adverse events by PEG-IFN and RBV would last. In
late 2013, the first all oral IFN-free regimens, sofosbuvir
plus ribavirin, for 12e24 weeks was approved in HCV ge-
notype 1e6 patients. The IFN-free therapy has the advan-
tages of higher response rates, less frequent dosing and
adverse events. Afterwards, novel IFN-free regimens
further increase the overall SVR rates over 90% by using
sofosbuvir plus ledipasvir, paritaprevir/ritonavir co-dosed
with ombitasvir and dasabuvir, grazoprevir plus elbasvir,
or daclatasvir co-dosed with asunaprevir and beclabuvir for
12 weeks (Table 1).8 These novel DAA regimens are easy to
use because of the low pill burden and short treatment
duration, devoid of complex on-treatment monitoring, and
few adverse predictors of responses. However, the pro-
hibitive costs of these new regimens preclude their wide-
spread use.
Over the past 25 years we have witnessed the miracle of
hepatitis C, from discovery to cure. During this time period,
three generations of Taiwanese hepatologists and scientists
made tremendous contribution to its discovery, prevention,
diagnosis, monitoring, and treatment.2 Although IFN-free
DAA regimens with SVR rates over 90% will come to
Taiwan sooner or later, the major challenges still remain in
terms of the prioritization and implementation of these
new treatment strategies because the price of these agents
is extremely high.
In summary, HCV cure through treatment is possible in
Taiwan but raises major public health issues that need to besolved through the collaboration among the national health
insurance system, pharmaceutical companies and medical
societies. Thus Taiwanese people can expect a future
without HCV infection.
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